Vukadinovi, D
This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
Quality matters enormously
Their role in specific areas, such as fat metabolism and weight loss, remains unclear and is not substantiated by significant clinical evidence
Springer, Heidelberg, pp 407467 Aydos SE, Ph D, Taspinar M et al (2009) Association of CYP1A1 and glutathione S-transferase polymorphisms with male factor infertility